AVITA Medical, Inc.
No SEC Form 4 filings for $RCEL in the last 30 days.
Avita Medical (NASDAQ:RCEL) shares rose about 21.7% in premarket after it reported record Q2 results. Revenue was $21.7M, up 18% YoY and about 8% above estimates. Adjusted loss per share narrowed to $0.25 vs $0.30 expected. Full-year 2026 revenue guidance raised to $86M-$89M and cash-flow breakeven targeted for Q4 2026. BTIG upgraded to Buy with a $7.00 target.
Avita Medical (RCEL) shares rose about 22% pre-open after the company reported Q2 revenue of $21.7M, up 18% YoY and about 8% above consensus, with adjusted loss per share of $0.25 vs $0.30 expected. The firm raised 2026 revenue guidance to $86M-$89M and reiterated cash-flow breakeven in Q4 2026. BTIG upgraded RCEL to Buy and set a $7 target.
AVITA Medical, Inc. (RCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rcel-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven VALENCIA, Calif., August 6, 2026 (GLOBE NEWSWIRE) — AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a
Over the past 7 days, alphai's AI scored 3 news stories mentioning RCEL (AVITA Medical, Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent RCEL coverage spans insider activity, earnings and market movers.
Earnings beat plus higher full-year guidance and a cash-flow breakeven roadmap are likely to sustain upside momentum near term.
The earnings beat plus raised revenue guidance and reaffirmed cash-flow breakeven are likely to sustain upside momentum near term.
Guidance raise plus a stated path to Q4 cash-flow breakeven is a direct fundamental catalyst for RCEL, with additional upside optionality from proposed CMS reimbursement changes for RECELL.
Pre-earnings momentum suggests traders are positioning for RECELL demand and loss trajectory updates.
Insider open-market purchase is a modest sentiment signal but typically has limited standalone impact on valuation.
alphai scores every news story that mentions RCEL with an AI model for sentiment and relevance, and aggregates insider trades from AVITA Medical, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Avita Medical (NASDAQ:RCEL) shares rose about 21.7% in premarket after it reported record Q2 results. Revenue was $21.7M, up 18% YoY and about 8% above estimates. Adjusted loss per share narrowed to $0.25 vs $0.30 expected. Full-year 2026 revenue guidance raised to $86M-$89M and cash-flow breakeven targeted for Q4 2026. BTIG upgraded to Buy with a $7.00 target.
4 min readAvita Medical (RCEL) shares rose about 22% pre-open after the company reported Q2 revenue of $21.7M, up 18% YoY and about 8% above consensus, with adjusted loss per share of $0.25 vs $0.30 expected. The firm raised 2026 revenue guidance to $86M-$89M and reiterated cash-flow breakeven in Q4 2026. BTIG upgraded RCEL to Buy and set a $7 target.
4 min readAVITA Medical, Inc. (RCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 rcel-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven VALENCIA, Calif., August 6, 2026 (GLOBE NEWSWIRE) — AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a
6 min readBiotech stocks rose Wednesday. Apollomics (APLM) jumped 22% after Nasdaq closed its MVLS compliance issue. Iovance (IOVA) gained 21% ahead of Q2 results; AVITA Medical (RCEL) rose 18% before Aug. 6 earnings; Annexon (ANNX) climbed 17% ahead of ARCHER II updates. Veradermics (MANE) gained 12% on Phase 2 hair-loss topline results.
7 min readWoody Joseph Fralin purchased 5,200 shares of AVITA Medical, Inc. (RCEL) at $4.00 on 2026-06-09.
2 min readWoody Joseph Fralin purchased 10,000 shares of AVITA Medical, Inc. (RCEL) at an average of $4.19 ($4.18–$4.20) across 2 trades on 2026-06-09.
1 min readAVITA Medical, Inc. (RCEL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 rcel-ex4_1.htm EX-4.1 EX-4.1 Exhibit 4.1 WARRANT certificate THIS WARRANT certificate HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ SECURITIES ACT ”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, S
2 min readWoody Joseph Fralin purchased 5,000 shares of AVITA Medical, Inc. (RCEL) at $4.09 on 2026-06-03.
1 min readWoody Joseph Fralin purchased 5,000 shares of AVITA Medical, Inc. (RCEL) at $4.10 on 2026-06-03.
2 min readWoody Joseph Fralin purchased 5,000 shares of AVITA Medical, Inc. (RCEL) at $4.21 on 2026-06-02.
3 min read
